These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32900254)

  • 1. Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study.
    Rivera R; Vilarrasa E; Ribera M; Roe E; Kueder-Pajares T; Zayas AI; Martínez-Molina L; Mataix Díaz J; Rodríguez-Nevado IM; Usero-Bárcena T; de la Mano D; García-Donoso C; Olveira A; Guinea G; Martín-Vázquez V; Ferran M
    J Dermatolog Treat; 2022 May; 33(3):1329-1338. PubMed ID: 32900254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France.
    Tournier A; Khemis A; Maccari F; Reguiai Z; Bégon E; Fougerousse AC; Amy de la Breteque M; Beneton N; Parier J; Boyé T; Avenel-Audran M; Girard C; Pallure V; Perrot JL; Bastien M; Mahé E; Beauchet A;
    Ann Dermatol Venereol; 2019 Feb; 146(2):106-114. PubMed ID: 30704943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decision-Analytic Modeling for Time-Effectiveness of the Sequence of Induction Treatments for Moderate to Severe Plaque Psoriasis.
    Zidane M; Dressler C; Gaskins M; Nast A
    JAMA Dermatol; 2019 Dec; 155(12):1380-1389. PubMed ID: 31617856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial.
    Salim A; Tan E; Ilchyshyn A; Berth-Jones J
    Br J Dermatol; 2006 Jun; 154(6):1169-74. PubMed ID: 16704650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
    Revicki D; Willian MK; Saurat JH; Papp KA; Ortonne JP; Sexton C; Camez A
    Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients.
    Cabello Zurita C; Grau Pérez M; Hernández Fernández CP; González Quesada A; Valerón Almazán P; Vilar Alejo J; Carretero Hernández G
    J Dermatolog Treat; 2017 Aug; 28(5):401-405. PubMed ID: 28001499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral fumaric acid esters for psoriasis.
    Atwan A; Ingram JR; Abbott R; Kelson MJ; Pickles T; Bauer A; Piguet V
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010497. PubMed ID: 26258748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients.
    Erduran F; Emre S; Hayran Y; Adışen E; Polat AK; Üstüner P; Öztürkcan S; Öztürk P; Ermertcan AT; Selçuk LB; Aksu EK; Akbaş A; Kalkan G; Demirseren D; Kartal SP; Topkarcı Z; Kılıç A; Yaldız M; Aytekin S; Hızlı P; Gharehdaghi S; Borlu M; Işık L; Botsalı BR; Solak EÖ; Albayrak H; Gönülal M; Balcı DD; Polat M; Daye M; Ataseven A; Yıldız S; Özer İ; Zorlu Ö; Doğan S; Erdemir VA; Dikicier BS
    Arch Dermatol Res; 2024 May; 316(6):278. PubMed ID: 38796658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial.
    Liu LF; Chen JS; Gu J; Xu JH; Jin HZ; Pang XW; Wang G; Yu C; Song ZQ; Guo ZP; Li W; Lai W; Cui PG; Chen M; Fang H; Lyu CZ; Li YZ; Sun Q; Xie HF; Liu XM; Gao XH; Shi YL; Zhao NQ; Zhang W; Zheng M
    Arch Dermatol Res; 2020 Aug; 312(6):437-445. PubMed ID: 31873772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
    Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.
    Chládek J; Simková M; Vanecková J; Hroch M; Chládkova J; Martínková J; Vávrová J; Beránek M
    Eur J Clin Pharmacol; 2008 Apr; 64(4):347-55. PubMed ID: 18163165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain.
    Daudén E; Vidal D; Romero A; Bordel MT; Rivera R; Márquez J; Zamora E; Martinez L; Ocaña MJ; Vila C; Iribarren P; Corona N; Zulaica A
    Actas Dermosifiliogr; 2024 Jan; 115(1):T1-T9. PubMed ID: 37923068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain.
    Daudén E; Vidal D; Romero A; Bordel MT; Rivera R; Márquez J; Zamora E; Martinez L; Ocaña MJ; Vila C; Iribarren P; Corona N; Zulaica A
    Actas Dermosifiliogr; 2024 Jan; 115(1):1-9. PubMed ID: 37429433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of methotrexate (0.3 mg/kg/week) versus a combination of methotrexate (0.15 mg/kg/week) with cyclosporine (2.5 mg/kg/day) in chronic plaque psoriasis: A randomised non-blinded controlled trial.
    Singh SK; Singnarpi SR
    Indian J Dermatol Venereol Leprol; 2021; 87(2):214-222. PubMed ID: 33769732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and Risk Factors of Hepatic Fibrosis in Psoriatic Patients Receiving Methotrexate with Concomitant Acitretin Therapy and Methotrexate Monotherapy.
    Rattanakaemakorn P; Pinyowiwat P; Iamsumang W; Chanprapaph K; Suchonwanit P
    Drug Des Devel Ther; 2021; 15():2299-2307. PubMed ID: 34093007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
    Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
    J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mycophenolate mofetil vs. methotrexate for the treatment of chronic plaque psoriasis.
    Akhyani M; Chams-Davatchi C; Hemami MR; Fateh S
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1447-51. PubMed ID: 20384673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term methotrexate therapy in psoriasis: a study of 197 patients.
    Kumar B; Saraswat A; Kaur I
    Int J Dermatol; 2002 Jul; 41(7):444-8. PubMed ID: 12121564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.